Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mart-1 adenovirus-transduced dendritic cells
- Development stage
- Phase 2
- Lead developer
- University of California, Los Angeles
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intravenous, Intradermal, Intranodal
01
Overview
MART-1 adenovirus-transduced dendritic cells are an autologous cellular immunotherapy designed to treat patients with MART-1-positive malignancies, primarily metastatic melanoma. This therapeutic approach involves harvesting peripheral blood mononuclear cells from a patient, which are then differentiated ex vivo into mature dendritic cells. These cells are subsequently transduced with a replication-deficient adenoviral vector carrying the gene for the Melanoma Antigen Recognized by T cells-1 (MART-1), also known as Melan-A. When re-infused into the patient, these genetically modified dendritic cells serve as potent antigen-presenting cells that process and display MART-1 epitopes via MHC Class I and II molecules. This presentation primes and activates a robust, antigen-specific cytotoxic T-lymphocyte (CTL) response and helper T-cell response aimed at recognizing and destroying melanoma cells that overexpress the MART-1 differentiation antigen.
- Other names
- Ad-MART-1 DCAd-MART1 DCAd-MART 1 DCadenoviral MART-1-transduced dendritic cellsMART-1-transduced autologous dendritic cellsMART1-transduced autologous dendritic cellsMART 1-transduced autologous dendritic cellsadenovirus-transduced MART-1 dendritic cell vaccine
02
Targets
MLANA (Melanoma antigen recognized by T cells 1)
Beyond the preview
Go deeper on mart-1 adenovirus-transduced dendritic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mart-1 adenovirus-transduced dendritic cells.